Related Experiment Video

Updated: Aug 17, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Do beta-blockers have a role in the treatment of chronic heart failure?

V Panfilov1, G Olsson

  • 1Cardiovascular Management & Strategies, Clinical R&D, Astra Hässle, S-431 83 Mölndal, Sweden.

Expert Opinion on Investigational Drugs
|January 1, 1997
PubMed

Insights

Beta-blockers show promise for chronic heart failure (CHF) by improving hemodynamics and quality of life. However, definitive proof of reduced mortality in CHF patients is still pending further large-scale trials.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Growing recognition of beta-blockers' role in chronic heart failure (CHF).
  • Complex mechanisms of action proposed for beta-blockade in CHF.
  • Primary rationale involves counteracting detrimental neurohormonal activation in CHF.

Purpose of the Study:

  • To evaluate the impact of beta-blockers on mortality in patients with chronic heart failure.
  • To summarize current evidence regarding the benefits and limitations of beta-blocker therapy in CHF.

Main Methods:

  • Review of existing literature and ongoing large-scale, prospective, randomized, placebo-controlled trials.
  • Analysis of effects on hemodynamics, exercise tolerance, and quality of life.

Main Results:

  • Positive effects observed on hemodynamics, exercise tolerance, and quality of life.
  • A trend towards improved prognosis noted, but no definitive proof of mortality reduction in CHF.
  • Several major trials are currently underway to provide conclusive evidence.

Conclusions:

  • Beta-blockers offer benefits in managing chronic heart failure symptoms and improving patient well-being.
  • Further research through ongoing large-scale trials is crucial to establish the definitive impact of beta-blockers on CHF mortality.

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.